'Deviated from the core': Akeso CEO tries to reset expectations of bispecific's survival readout amid market tumult
As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD-(L)1xVEGF world, Akeso CEO Michelle Xia, Ph.D., figured that it’s high time the company recalibrates investors’ expectations.
As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD-(L)1xVEGF world, Akeso CEO Michelle Xia, Ph.D., figured that it’s high time the company recalibrates investors’ expectations.
